Holen Sie sich die Stockscreener-App
102.01
0.81%
-0.86
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$102.87
Offen:
$102.51
24-Stunden-Volumen:
2.95M
Relative Volume:
0.27
Marktkapitalisierung:
$177.33B
Einnahmen:
$44.33B
Nettoeinkommen (Verlust:
$6.50B
KGV:
27.44
EPS:
3.717
Netto-Cashflow:
$7.40B
1W Leistung:
+0.16%
1M Leistung:
-6.86%
6M Leistung:
-23.70%
1J Leistung:
-18.00%
1-Tages-Spanne:
$101.85
$103.08
1-Wochen-Bereich:
$100.88
$103.79
52-Wochen-Spanne:
$100.88
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
102.05 | 178.75B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
331.17 | 126.97B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.46 | 111.22B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.26 | 93.36B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.03 | 46.73B | 6.07B | 1.06B | 1.34B | 1.8063 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Medical Foods Market Is Going to Boom |• Abbott • Danone - openPR.com
Rathbones Group PLC Increases Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Holdings Reduced by Cidel Asset Management Inc. - MarketBeat
Abbott Laboratories $ABT Shares Acquired by BXM Wealth LLC - MarketBeat
Abbott India Ltd stock: What you need to know for smart investing now - AD HOC NEWS
The Best Dividend ETF to Buy in April 2026 If You Want Passive Income - The Motley Fool
Abbott Laboratories Embarks on a Transformative $23 Billion Acquisition - AD HOC NEWS
ABT SEC FilingsAbbott Labs 10-K, 10-Q, 8-K Forms - Stock Titan
Abbott launches nationwide campaign on National Vitamin C Day to highlight role of micronutrient in wellness - MediaNews4U
A Dividend Dynasty: Abbott Laboratories' Enduring Payout Streak - AD HOC NEWS
Exact Sciences Corp. stock: Acquired by Abbott – What it means for you now - AD HOC NEWS
Erste Group Keeps Their Hold Rating on Abbott Laboratories (ABT) - The Globe and Mail
Abbott Stock Sits 26% Off Its Peak While Analysts Back a $132 Mean Price Target - TIKR.com
Abbott Laboratories (ABT) latest stock news and headlines - Yahoo Finance Singapore
Analysts’ Top Healthcare Picks: Abbott Laboratories (ABT), Cogent Biosciences (COGT) - The Globe and Mail
Aberdeen Group plc Increases Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott India Ltd Stock: A Stable Player in India's Booming Healthcare Sector for Long-Term Investors - AD HOC NEWS
What Abbott Laboratories (ABT)'s Oncology Test Integration Into OncoEMR Means For Shareholders - simplywall.st
Abbott Laboratories (ABT) director receives 382 stock equivalent units as fees - Stock Titan
Director at Abbott (NYSE: ABT) receives stock equivalent unit award - Stock Titan
Abbott (ABT) director Gonzalez receives 321 stock equivalent units as fees - Stock Titan
Abbott (ABT) director Robert Alpern awarded 76 stock equivalent units as fees - Stock Titan
Abbott Laboratories (ABT) director Nita Ahuja granted 102 stock equivalent units - Stock Titan
Sinocare Can't Scrap Abbott's Glucose Monitor Ban At UPC - Law360
Compagnie Lombard Odier SCmA Makes New Investment in Abbott Laboratories $ABT - MarketBeat
Abbott India Ltd Stock: Steady Growth in India's Pharmaceutical Sector Amid Evolving Healthcare Dema - AD HOC NEWS
Bank Pictet & Cie Europe AG Decreases Position in Abbott Laboratories $ABT - MarketBeat
Banque Pictet & Cie SA Sells 83,130 Shares of Abbott Laboratories $ABT - MarketBeat
Drug Delivery Device Market Is Booming Worldwide 2026-2033 | - openPR.com
Abbott Laboratories Expands into Wearable Technology Through Whoop Investment - AD HOC NEWS
Abbott’s Whoop Investment Puts Digital Health Wearables On Shareholders’ Radar - Yahoo Finance
Assessing Abbott Laboratories (ABT) Valuation After New Flatiron Health Oncology Integration - simplywall.st
Abbott Laboratories completed the acquisition of North Island Assets of Synlait Milk from Synlait Milk Limited. - MarketScreener
Abbott joins $575M funding round for wearable maker Whoop - MassDevice
Abbott: A Brighter Investment Case Heading Into Q1 Earnings (Rating Upgrade) (NYSE:ABT) - Seeking Alpha
Best Healthcare Stocks to Buy Right Now for Long-Term Growth - The Motley Fool
Reasons to Retain Abbott Stock in Your Portfolio Now - TradingView
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock - Yahoo Finance
20,751 Shares in Abbott Laboratories $ABT Bought by Shrier Wealth Management LLC - MarketBeat
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Edwards Lifesciences (EW) and Palisade Bio (PALI) - The Globe and Mail
Abbott Laboratories Pakistan : Change in Date and Time of the 77th Annual General Meeting - MarketScreener
List of 29 Acquisitions by Abbott (Apr 2026) - Tracxn
Whoop raises $575M—Abbott, LeBron James, Cristiano Ronaldo among the investors - Cardiovascular Business
Abbott Oncology Integration Into OncoEMR Tests Long Term Growth Story - simplywall.st
Whoop raises $575M, adds Abbott as strategic investor - medtechdive.com
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Abbott Laboratories (ABT) - The Globe and Mail
Abbott integrates Precision Oncology portfolio into Flatiron’s OncoEMR - Yahoo Finance
BTIG Research Lowers Abbott Laboratories (NYSE:ABT) Price Target to $131.00 - MarketBeat
BTIG Research Adjusts Abbott Laboratories PT to $131 From $140, Maintains Buy Rating - marketscreener.com
Whoop Raises $575M at $10.1B Valuation, Abbott Joins as Investor - Athletech News
Abbott Laboratories $ABT Position Trimmed by J. Safra Sarasin Holding AG - MarketBeat
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):